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ABSTRACT 
Introduction: Familial amyloid neuropathy (FAP) with transthyretin Val30Met mutation 
(ATTR-FAP) is the most common type of FAP. Although several authors have previously 
reported a size-dependent fiber loss in ATTR-FAP, predominantly involving unmyelinated 
and small diameter myelinated fibers (MF), the mechanisms of nerve fiber loss have not 
been fully understood.  
Objective: To establish the morphometric pattern of peripheral neuropathy in hereditary 
ATTR-FAP (symptomatic and asymptomatic subjects) and acquired form of ATTR-FAP, 
and to compare pathological and clinical features between these groups.  
Methods: We analyzed sural nerve biopsies from 98 patients with Val30Met ATTR-FAP, 
37 ATTR-FAP asymptomatic mutation carriers, and 10 patients with acquired ATTR-FAP, 
aged between 17 and 84 years, which were performed between 1981 and 2017 at Centro 
Hospitalar do Porto.  
Results: The mean age at nerve biopsy was 32.2 ± 13.3 years for asymptomatic mutation 
carriers, 47.5 ± 14.8 years for ATTR-FAP patients, 62.4 ± 3.7 years for de novo ATTR-
FAP, and 46.5 ± 18.4 years for controls. The mean duration between nerve biopsy and 
symptoms onset was 9.2 ± 7.3 years (range from 1 to 27 years) in the asymptomatic 
carriers, and from liver transplantation to disease onset was 7.1 ± 2.7 years (range from 4 
to 13 years) in the acquired ATTR-FAP cases. ATTR-FAP patients had loss of all fiber 
type modalities compared to both asymptomatic carriers and controls (p<0.001), whereas 
asymptomatic carriers showed loss of small myelinated fibers when compared to controls 
(p<0.05). Acquired ATTR-FAP patients revealed similar pathological findings to their 
inherited counterparts, but with lesser degrees of fiber loss for the same disease clinical 
stage (p<0.01). There was a positive correlation between myelinated fiber density and 
time gap to symptoms onset in the asymptomatic carriers that developed early-onset form 
of the disease, being this correlation only statistically significant for the large MF (r=0.52, 
p<0.01). Subjects with amyloid deposition in sural nerve biopsies developed symptoms 
earlier than those with no amyloid. No statistical differences were observed regarding the 
MF density and the amyloid deposition between the early- and late-onset cases. The loss 
of MF increased with disease progression, and patients in more advanced clinical stage 
showed more frequent amyloid deposition in the nerve.  
iii 
Conclusions: This study confirms that small fiber size loss is an initial event in ATTR-FAP, 
already present in asymptomatic gene carriers, starting several years before symptoms 
onset. We show for the first time that large MF loss and amyloid deposition are 
pathological features that correlate independently with short period to symptoms onset for 
asymptomatic carriers that developed early-onset form of the disease.  
 
Keywords: amyloidosis; familial amyloid neuropathy; nerve fibers; pathology; sural serve; 
transthyretin 	 	
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RESUMO 
Introdução: A polineuropatia amiloidótica familiar (PAF) associada à mutação Val30Met 
no gene da transtirretina (PAF-ATTR) é a forma mais comum de PAF. Vários autores 
descreveram previamente uma perda de fibras tamanho dependente, com envolvimento 
preferencial das fibras não mielinizadas e das fibras mielinizadas (FM) de pequeno 
diâmetro, contudo esse mecanismo de perda não está totalmente esclarecido. 
Objetivo: Estabelecer o padrão morfométrico de neuropatia periférica na forma hereditária 
(em sintomáticos e assintomáticos) e adquirida de PAF-ATTR, e comparar as 
caraterísticas patológicas e clínicas entre os grupos. 
Métodos: Analisámos biópsias de nervo sural de 98 doentes com a mutação Val30Met de 
PAF-ATTR, de 37 portadores assintomáticas e de 10 doentes com forma adquirida de 
PAF-ATTR, com idades entre os 17 e os 84 anos, que foram realizadas entre 1981 e 
2017 no Centro Hospitalar do Porto. 
Resultados: A idade média, em anos, à data da biópsia foi de 32.2 ± 13.3 nos portadores 
assintomáticos, 47.5 ± 14.8 nos doentes com PAF-ATTR, 62.4 ± 3.7 nos doentes com 
PAF-ATTR adquirida e 46.5 ± 18.4 nos controlos. A duração media, em anos, entre a 
biópsia de nervo e o início de sintomas foi de 9.2 ± 7.3 (variando entre 1 e 27) nos 
portadores assintomáticos, e entre a transplantação hepática e o início de sintomas foi de 
7.1 ± 2.7 (variando entre 4 e 13) nos doentes com PAF-ATTR adquirida. Os doentes com 
PAF-ATTR apresentaram perda de todas as classes de fibras, comparando com os 
portadores assintomáticos e os controlos (p<0.001), enquanto que os portadores 
assintomáticos apresentaram perda das pequenas FM quando comparados com os 
controlos (p<0.05). Os doentes com PAF-ATTR adquirida revelaram achados patológicos 
idênticos aos homólogos hereditários, embora com uma taxa inferior de perda de fibras 
para os mesmos estadios clínicos (p<0.01). Encontrámos uma correlação positiva entre a 
densidade de fibras mielinizadas e o intervalo de tempo até ao início de sintomas nos 
portadores assintomáticos que desenvolveram a forma precoce da doença, sendo que 
esta correlação apenas se mostrou estatisticamente significativa para as FM de grande 
diâmetro (r=0.52, p<0.01). Indivíduos com depósitos de amiloide na biópsia 
desenvolveram sintomas mais precocemente do que os sem depósitos de amiloide. Não 
foram observadas diferenças estatísticas entre os doentes com forma precoce e os 
v 
doentes com a forma tardia de PAF-ATTR. A perda de FM aumentou com a progressão 
clínica da doença, e doentes em estadios clínicos mais avançados apresentaram 
deposição de amiloide na biópsia com maior frequência. 
Conclusão: Este estudo confirma que a perda de pequenas fibras é um evento inicial na 
PAF-ATTR, estando já presente em portadores assintomáticos, e que começa anos antes 
do início de sintomas. Mostrámos, pela primeira vez, que a perda de grandes FM e a 
deposição de amiloide são caraterísticas patológicas que se correlacionam de forma 
independente com períodos mais curtos para o início de sintomas em portadores 
assintomáticos que desenvolveram a forma precoce da doença. 
 
Palavras-chave: amiloidose; fibras nervosas; nervo sural; neuropatia amiloidótica familiar; 
patologia; transtirretina 
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INTRODUCTION 
Familial amyloid polyneuropathy (FAP) is a hereditary multisystemic disease, with 
autosomal dominant transmission, characterized by the extracellular deposition of 
insoluble fibril aggregates, predominantly affecting unmyelinated and small diameter 
myelinated fibers. FAP can be divided into three main types, considering the precursor of 
the amyloid protein – transthyretin (ATTR), apolipoprotein A-1 (AApoAI) and gelsolin 
(AGel). The amyloidosis resulting from the deposition of mutated transthyretin is, among 
all the forms, the most common and has the worst prognosis, leading to patients’ death 
within an average period of 10 years after diagnosis. 1, 2  
Corino de Andrade first described FAP in 19523, and later the genetic basis was 
identified: the substitution of methionine for valine at position 30 (Val30Met).4 Currently, 
over 150 mutations of the TTR gene are known, most of them amyloidogenic, producing a 
broad range of phenotypes.5  
Clinically, FAP with thransthyretin mutation (ATTR-FAP) is characterized by an 
axonal, sensorimotor and autonomic polyneuropathy, with onset of symptoms during third 
and fifth decades of life in early-onset patients, and decades later in the late-onset FAP 
patients.1, 6-8 These two groups differ in some clinical and pathological features; 
nonetheless, the reason for that has not yet been fully elucidated.6-10 Extra-neurological 
manifestations, including, renal, ocular, cardiac, hematological, and metabolic 
abnormalities may also be present, increasing morbidity and mortality in these patients.5, 
11-13 Even though the Nomenclature Committee of International Society of Amyloidosis 
(ISA) recommends the use of the protein name to refer the disease, FAP is also 
considered an appropriated term as it is widely used in the neurology literature.14 
Recently, several authors have described a form of acquired ATTR amyloidosis in 
patients undergoing Domino Liver Transplantation (DLT), a surgical procedure in which 
the liver from an ATTR-FAP patient (functionally and anatomically normal) is removed and 
transplanted into another recipient, whom starts developing de novo amyloid neuropathy 
after a median of 7 years following transplantation.15-18  
Morphometry of sural nerve biopsies is an important diagnostic tool of peripheral 
neuropathies as it provides quantitative and objective details, and enables us to evaluate 
the progression of disease and the treatment response.19, 20 However, this is an invasive 
procedure, nowadays reserved for selected cases only. Three compartments form part of 
the basic structure of the sural nerve – the epineurium, perineurium and endoneurium, 
and five to fifteen nerve fascicles are usually present in it.21, 22 The normal density of 
myelinated axons is between 7000 and 10000 fibers/mm2 in young adults, with an age-
		 2 
dependent decrease.21-23 The diameter of the myelinated fibers ranges from 2 to 17µm, 
showing a bimodal distribution with peaks between 3-6µm and 9-12µm. The g-ratio (ratio 
of axon diameter to fiber diameter) is useful to assess the severity of demyelination, and 
in normal conditions varies between 0,5 and 0,7.21, 22, 24 
Previous morphological and morphometric studies of sural nerve biopsies in ATTR-
FAP have already reported the pathological changes in nerve fibers, but the exact 
mechanism of nerve fiber loss remains unknown.6, 25-28 The primary objective of this study 
was to establish the morphometric pattern of peripheral neuropathy in hereditary and 
acquired ATTR amyloidosis, and to assess if there is any relation between the density of 
myelinated fibers and the clinical characteristics of the disease. Some of these results had 
been previously reported.25, 26 We extended the number of analyzed cases in the 
asymptomatic gene carriers and ATTR-FAP patients, added follow-up clinical data for 
analysis, and studied for the first time patients with acquired ATTR amyloidosis. The 
establishment of the morphometric pattern, as well as the identification of potential clinical 
correlations, is therapeutically relevant, as it would allow for a better interpretation of the 
role of disease-modifying agents in ATTR-FAP. 
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MATERIALS AND METHODS 
Patients  
We analyzed sural nerve biopsies from 98 patients with Val30Met ATTR-FAP, 37 
ATTR-FAP asymptomatic mutation carriers, and 10 patients with acquired ATTR 
amyloidosis, aged between 17 and 84 years, which were performed between 1981 and 
2017 at hospital Centro Hospitalar do Porto (CHP). Patients with an onset of symptoms 
before the age of 50 were classified as early-onset cases, and those with an onset age 
over 50 years were classified as late-onset cases.8, 9, 29  
Thirty-one sural nerve biopsies from subjects who were classified as normal by 
experienced neuropathologists have been selected from the Neuromuscular Database of 
the Neuropathology Unit of CHP and used as control. Additionally, clinical records were 
reviewed to exclude history of any neurological disorder that could affect the peripheral 
nerve composition.  
All aspects associated with the current study were approved by the Ethics Committee 
of CHP. 
 
Clinical and demographic assessments  
Clinical and demographic data were obtained from the database of the Corino de 
Andrade Unit and by consulting the patients’ clinical records. The following data were 
collected: gender, age at onset of symptoms, age at the time of sural nerve biopsy, age at 
the time of DLT, presence of family ATTR amyloidosis history, and presence of 
comorbidities. The family ATTR amyloidosis history was considered to be positive in 
cases with the presence of one first or second-degree relative with symptomatic ATTR-
FAP. 
The Polyneuropathy Disability (PND) score, an useful disease staging tool in the 
evaluation of peripheral sensory and motor disturbances in FAP patients12, was calculated 
by consulting patients’ medical records, in order to establish the stage of disease at the 
time of nerve biopsy. ATTR-FAP patients were stratified by the following PND stages: 
stage I – sensory disturbances with preserved walking capability; stage II – sensory and 
motor deficits but ability to walk without any support; stage IIIA – walking only with the 
help of one stick or crutch; stage IIIB – walking with the help of two sticks or crutches; 
stage IV - confined to a wheelchair or bedridden. 
 
Sural nerve specimens  
The sural nerve was exposed at the level of lateral malleolus, under local anesthesia, 
and a fascicular nerve biopsy was performed.30, 31 The sural nerve specimens were 
divided into two portions. The first one was fixed in 2,5% glutaraldehyde on phosphate-
		 4 
buffered saline solution at pH 7,4, dehydrated with numerous alcohol passages and 
embedded in epoxy resin. Semithin transverse sections (1 µm thick) were cut and stained 
with 1% toluidine blue solution for morphometric study.9, 28 The second portion of the 
specimen was fixed in 10% formalin solution and embedded in paraffin. Sections were cut 
by routine methods and stained with hematoxylin and eosin and Congo red. The presence 
of amyloid deposits was detected by Congo red staining, exhibiting an apple-green 
birefringence under polarized light (figure1).  
 
Morphometric analysis  
A semi-automated analysis of the density of myelinated fibers was carried out using the 
Leica Application Suite (LAS) V4.5 and Fiber software. For each nerve, 3 to 4 digital 
images were captured by a digital camera (Leica MC170 HD) incorporated on a light 
microscope (Leica DM 4000 B), under a 63x objective, in order to cover the maximum 
nerve area (figure 2). The total, the large (>7 µm), and the small (≤ 7 µm) myelinated fiber 
(MF) densities 23, 32 were calculated, as also as the mean fiber diameter, the mean g-ratio 
and the ratio of small to large MF densities for patients with a total myelinated fiber density 
≥100/mm2  
 
Statistical analysis  
Subjects’ data are reported as numbers and percentages for categorical variables, and 
as medians with interquartile range medians or as means ± SD for continuous variables.  
Due to asymmetrical distribution and non-homogeneity of variances of the majority of 
the parameters, statistical analyses were performed with the non-parametric tests 
Pearson’s Chi-square, Mann-Whitney test, and Kruskal-Wallis test for independent 
samples, using IBM SPSS® Statistics24 software. Values of p<0,05 were considered 
significant. 
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Figure 1. – Representative characteristics of amyloid deposition in the sural nerve from a ATTR-
FAP patient. (A) Hematoxylin and eosin staining. (B) Immunostaining with anti-human transthyretin 
(TTR) antibody. (C) Congo red staining. (D) Congo red staining under polarized light, 
Figure 2. – Semi-automated morphometry. Representative semithin cross-section of a sural 
nerve’s endoneurial area from an ATTR-FAP patient, under a x63 objective. (A to D). (B) Manual 
correction to remove the wrongly delineated areas. (C and D) Myelin sheaths marked in blue and 
axons marked in red.  
A B 
C D 
A 
C D 
B 
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RESULTS 
1. Pathological findings in ATTR-FAP asymptomatic mutation carriers, ATTR-FAP 
patients and de novo ATTR amyloidosis patients.  
Demographic and morphometric data are summarized in table I. The mean age at 
nerve biopsy was 32.2 ± 13.3 years for asymptomatic mutation carriers, 47.5 ± 14.8 years 
for ATTR-FAP patients and 62.4 ± 3.7 years for de novo ATTR amyloidosis patients. In 
the asymptomatic carriers, the mean duration between nerve biopsy and symptom onset 
was 9.2 ± 7.3 years, ranging from 1 to 27, and the mean time from symptom onset to 
patients’ death was 12.3 ± 4.0. In ATTR-FAP patients, the average time from onset of 
neuropathy to nerve biopsy was 3.4 ± 3.1 years, and the mean time from onset of 
symptoms to death was 10.8 ± 6.3 years. Except for the asymptomatic mutation carriers, 
the proportion of men was higher in the ATTR-FAP patients and control groups, although 
these differences were not statistically significant. 
The de novo ATTR amyloidosis group included 9 men and 1 woman, none of whom 
had symptoms of polyneuropathy previously to DLT. The indications for liver 
transplantation were alcoholic cirrhosis (n=6), hepatocellular carcinoma (HCC) (n=1), 
hepatitis B virus (HBV) cirrhosis (n=1), hepatitis C virus (HCV) cirrhosis (n=1), and 
hemochromatosis (n=1). These patients underwent DLT between 2001 and 2007. The 
mean age at DLT was 54.2 ± 4.9; the mean duration between DLT and onset of 
symptoms was 7.1 ± 2.7 years (range from 4 to 13 years). The mean time from onset of 
neuropathy to nerve biopsy was 1.1 ± 1.3 years, and the mean time between onset of 
symptoms and patients’ death was 3.8 ± 1.7 years.  
Table I – Demographic, clinical and morphometric features of ATTR-FAP, acquired ATTR and control subjects 
Features Controls (n=31) 
Asymptomatic 
mutation carriers 
(n=37) 
ATTR-FAP patients Acquired ATTR 
amyloidosis 
patients (n=10) 
All patients 
(n=98) 
Early-onset 
cases (n=60) 
Late-onset 
cases (n=38) 
Male sex, % (n) 58.1 (18) 48.6 (18) 55.1 (54) 51.7 (31) 60.5 (23) 90 (9) 
Age at onseta, yr NA 39.6 ± 13.4ξ 44.1 ± 14.3 34.5 ± 7.5 59.4 ± 7.3 61.1 ± 3.5 
Age at nerve biopsya, yr 46.5 ± 18.4 32.2 ± 13.3 47.5 ± 14.8 37.5 ± 8.3 63.4 ± 6.5 62.4 ± 3.7 
Pathology of the sural nervea      
Total myelinated fiber 
density, n/mm2 9072 ± 1967 7766 ± 1286 1742 ± 2167 1983 ± 2128 1361 ± 2203 4138 ± 2815 
Large myelinated fiber 
density, n/mm2 3940 ± 1031 4427 ±1013 1060 ± 1211 1262 ± 1277 741 ± 1035 2299 ± 1374 
Small myelinated fiber 
density, n/mm2 5131 ± 1430 3339 ± 792 686 ± 1072 720 ± 947 632 ± 1256  1839 ± 1543 
Ratio small/largeb 1.2 [1.0-1.6] 0.8 [0.6-0.9] 0.6 [0.3-1.1] 0.5 [0.3-0.8] 0.8 [0.2-1.6] 0.6 [0.5-1.3] 
Fiber diameter, µmc 7.5 ± 0.6 8.6 ± 0.7  8.7 ± 1.8* 8.9 ± 1.7# 8.5 ± 1.8¶ 8.4 ± 0.9 
g-ratioc 0.52 ± 0.05 0.50 ± 0.06 0.49 ± 0.06* 0.50 ± 0.06# 0.49 ± 0.06¶ 0.48 ± 0.05 
ATTR-FAP – familial amyloid polyneuropathy with thransthyretin mutation; ATTR – thransthyretin; NA – not applicable  
a Values are expressed as mean ± SD; 
b Values are expressed as median [interquartile range] 
c Results are presented for patients with total myelinated fiber densities ≥100/mm2 
ξ n=32 (from asymptomatic TTR mutation carriers who developed symptoms during the 27 years of clinical follow-up); *n=87; #n=54;¶n=33 
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1.1 Comparison between ATTR-FAP asymptomatic mutation carriers, ATTR-FAP 
patients and controls  
ATTR-FAP patients had a total MF density of 1742 ± 2167 fibers/mm2, exhibiting loss 
of large (Z= –7.11; p < 0.001) and small MF (Z= –6.88; p < 0.001) when compared to 
controls and asymptomatic mutation carriers (figure 3). These patients also presented 
greater MF diameters compared to both controls and asymptomatic mutation carriers (p < 
0.001) and lower mean g-ratio (Z= –2.94; p = 0.01) than controls.  
The asymptomatic mutation carriers presented depletion of small MF (Z= –2.46; 
p=0.041) and greater mean MF diameter (Z= 4.29; p < 0.001) compared to controls. The 
g-ratio did not differ from control group.  
The medians of the ratios of small to large MF densities of both ATTR-FAP patients 
and asymptomatic carriers were lower than the one of the controls (Z= –5.65, p<0.001; Z= 
–4.00, p <0.001, respectively), meaning that the majority of these subjects had a higher 
proportion of large than small MF in relation to controls (figure 4).  
Amyloid deposition was found in a significantly lower proportion of asymptomatic 
carriers than of ATTR-FAP patients (32% versus 86%, respectively; p < 0.001). 
Figure 3. – Density of myelinated fibers (total, large and small) and distribution of the mean g-ratio 
in controls, asymptomatic mutation carriers and ATTR-FAP patients. **p≤0.01 ***p≤0.001 (Kruskal-
Wallis test)  
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Figure 4a. – Normal morphometric findings in sural nerve specimen. (A to C) Photomicrographs of 
1µm transversal sections from a control’s sural nerve (stained with toluidine blue). Graphic D 
shows a diameter frequency histogram of myelinated fibers in sural nerve from a control, exhibiting 
a typical bimodal distribution of fiber diameters, with higher proportion of small myelinated fiber 
than of large myelinated fibers. 
 
Figure 4b. – ATTR-FAP morphometric findings in sural nerve specimen. Photomicrographs of 1 
µm transversal sections from a ATTR-FAP patient’s sural nerve (A) and an asymptomatic mutation 
carrier’s sural nerve (B) (stained with toluidine blue). In A, there is a severe depletion of both small 
and large myelinated fibers; in B there is a moderate loss of small myelinated fibers. Graphic C 
shows a diameter frequency histogram of myelinated fibers in sural nerve from a ATTR-FAP 
patient, exhibiting loss of the bimodal distribution of fiber diameters. Graphic D shows a diameter 
frequency histogram of myelinated fibers in sural nerve from an asymptomatic mutation carrier, 
presenting a higher peak of large than of small myelinated fibers, in contrast to the fiber distribution 
in controls. 
A B 
C D 
A 
B 
C 
D 
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2. Clinicopathological correlations  
2.1. Asymptomatic mutation carriers 
Correlation between MF density, amyloid deposition and time to disease onset  
When considering the total group of asymptomatic mutation carriers, no correlation 
was found between the morphometric variables and the time gap to disease onset. 
Considering the subgroup that developed early-onset form of the disease, there was a 
positive correlation between total MF density and time to disease onset (r= 0.52; p<0.01). 
As shown in figure 5A, a higher density of MF at the time of nerve biopsy allowed a longer 
period free-of-disease. Interestingly, when analyzing this correlation separately according 
to the myelinated fiber size, this correlation was only significant for large MF density 
(figure 5B). 
In this group, 12 cases presented amyloid in their sural nerve biopsy (32%). These 
cases developed symptoms earlier (the mean time to disease onset 4.4 ± 3.4 years) 
compared to the asymptomatic subjects without amyloid deposition (11.4 ± 7.6 years; Z= 
–2.84, p=0.003). This group showed younger age at symptom onset (32 years in amyloid 
group vs 43 in the non-amyloid group). Interestingly, when considering only the cases that 
developed the early-onset form of the disease, the time to disease onset remained shorter 
for the subjects with amyloid deposition (4.4 vs 8.1 years; Z= –2.06, p = 0.041) despite the 
similar age of onset between the groups (32 vs 35 years). Nevertheless, two patients with 
amyloid deposits in nerve biopsy started developing symptoms after a period of 10 years. 
There were no differences in any of the evaluated morphometric parameters when 
comparing asymptomatic mutation carriers with or without amyloid deposits, considering 
either all subjects or the group that develop early-onset form of disease.  
A multiple regression model, with the time gap from nerve biopsy to disease onset as 
the dependent variable, and myelinated fiber density, amyloid deposition and sex as 
predictors, showed that all these variables had a statistically significant contribution, with 
an explanatory power of R2=56% of the observed variance. Moreover, amyloid deposition 
and sex had negative coefficients, meaning that the time gap between nerve biopsy and 
disease onset decreased with the increasing of the values of amyloid deposition, and was 
smaller for the male sex. On the other hand, a higher myelinated fiber density (with a 
small positive coefficient) implied an increasing of the dependent variable. 
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Figure 5. – (A) Correlation between the total myelinated fiber density and the time to symptoms 
onset in ATTR-FAP patients who developed early form of disease (r=0.52; p=0.008). (B) 
Correlation between the large (blue) and small (red) myelinated fibers densities, and the time to 
symptoms onset in ATTR-FAP patients who developed early form of disease. A positive correlation 
was observed only between the large myelinated fibers density and the time to disease onset 
(r=0.52;p=0.008). 
 
2.2. ATTR-FAP patients 
Correlation between MF density, amyloid deposition and clinical stages 
The distribution of the ATTR-FAP patients by clinical stages is summarized in table II.  
The PND score was assessed in 92 patients: 48.9% had only sensory disturbances (stage 
I), 44.6% exhibited impaired walking capability but without requiring any support (stage II), 
and 5.5% were able to walk only with help (stage III). One patient was confined to a 
wheelchair at time of nerve biopsy (stage IV). To establish a correlation between the total 
MF density and the clinical stage we considered only ATTR-FAP patients at PND stages I 
and II, due to the low number of patients in other clinical stages.  
Patients in clinical stage I of PND score presented a mean density of MF per mm2 of 
2886 ± 2483, which revealed to be higher than of the patients in clinical stage II of PND 
score (720 ± 1313 MF/mm2; Z= -5.84, p<0.001). The same difference between the two 
clinical stages was also observed for the large (Z= –5.64, p<0.001) and small MF 
densities (Z= -5.61, p<0.001). The mean time between onset of symptoms and nerve 
biopsy was higher in patients with stage II compared to patients with stage I (4.8 ± 3.3 vs 
1.9 ± 2.5 years, respectively; Z= 5.14, p<0.001). In the same direction, there was a weak 
negative correlation between the time from symptom onset to nerve biopsy and total MF 
densities (r= –0.266, p < 0.05). This negative correlation was stronger for large myelinated 
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fibers density (r= –0.370, p<0.001) and there was no correlation with small MF densities. 
We also found a weak positive correlation between MF densities (total and large MF) and 
disease duration (time to death) after nerve biopsy (r=0.270, r=0.319; p<0.05; 
respectively). 
Considering the amyloid deposition, all 41 patients in clinical stage II of PND score 
exhibited amyloid in their nerve biopsy versus 35 of 45 patients in clinical stage I of PND 
score (p=0.001). Comparing the MF density of ATTR-FAP patients according to the 
presence or absence of amyloid deposition (10 without amyloid versus 76 with amyloid), 
the group with no amyloid showed higher total (Z= –3.44, p=0.001), large (Z= –3.42, 
p=0.001) and small (Z= –3.46, p=0.001) MF densities than those with positive amyloid 
(table III). Disease duration and age at biopsy were similar in both groups. There was a 
tendency for age at disease onset to be lower in the group with amyloid (p=0.051).  
 
Early- versus late-onset cases (MF density and clinical stages) 
In the early-onset cases, the mean density of total MF was 1983 ± 2128 fibers/mm2 
(21% of age-matched control density; p<0.001). Their mean density of large MF was 1262 
± 1277 fibers/mm2 (29% of age-matched control density; p<0.001) and that of small MF 
was 720 ± 947 fibers/mm2 (14% of age-matched control density; p<0.001). In late-onset 
cases, the mean density of total MF was 1361 ± 2203 fibers/mm2 (17% of age-matched 
control density; p<0.001), the mean density of large MF was 741 ± 1035 fibers/mm2 (22% 
of age-matched control density; p<0.001) and that of small MF was 632 ± 1256 fibers/mm2 
(14% of age-matched control density; p<0.001).  
The distribution of PND stages differed between these two groups; 61.5% of the early-
onset patients were at stage I at time of nerve biopsy against 38.5% of the late-onset 
cases (p=0.034), who were predominantly in advanced clinical stages. The late-onset 
cases presented a higher mean time gap from symptoms to nerve biopsy than did early-
onset patients (4.0±3.2 versus 3.0±3.0 years), however this difference did not reach 
statistical significance. In early-onset cases, a negative correlation was found between the 
time from onset of symptoms to nerve biopsy and the total and large MF densities (r= –
0.361, p=0.005; r= –0.439, p=0.001; respectively). This correlation was not found for the 
late-onset group.  
Despite more frequent in the early onset group, no statistically significant differences 
were observed regarding the presence of amyloid deposition between the two groups 
(92% in early- versus 82% in late-onset cases). 
A positive family history was found in a higher proportion of early-onset cases than of 
late-onset cases (82% versus 44%, respectively; p<0.001).  
		 12 
Table II – Clinical stages of ATTR-FAP patients according to PND score 
 All patients (n=92) 
Early-onset cases 
(n=55) 
Late-onset cases 
(n=37) 
PND score, % (n)    
Stage I 48.9 (45) 58.2 (32) 35.1 (13) 
Stage II 44.6 (41) 36.4 (20) 58.8 (21) 
Stage IIIa 3.3 (3) 1.8 (1) 5.4 (2) 
Stage IIIb 2.2 (2) 1.8 (1) 2.7 (1) 
Stage IV 1.1 (1) 1.8 (1) 0 
ATTR-FAP – familial amyloid polyneuropathy with thransthyretin mutation; PND – Polyneuropathy Disability 
 
2.3 De novo ATTR amyloidosis patients 
Due to the advanced age at biopsy in de novo ATTR amyloidosis patients, clinical 
features and morphometric studies were compared with control and ATTR-FAP patients 
who had undergone nerve biopsy within the same age range than of de novo ATTR 
amyloidosis patients (58 to 69 years). The mean time from onset of neuropathy to nerve 
biopsy was shorter in de novo ATTR amyloidosis patients compared to ATTR-FAP 
patients (1.1 ± 1.3 years vs 5.3 ± 3.9 years; Z = 12.73, p<0.001), and the mean time 
between onset of symptoms and patients’ death was considerably lower in de novo ATTR 
amyloidosis patients (3.8 ± 1.7 years) when compared to the one in ATTR-FAP patients in 
the same preceding conditions (8.8 ± 2.7; Z= 6.951, p = 0.008).  
The PND score at time of nerve biopsy was statistically different between the ATTR-
FAP and the de novo ATTR amyloidosis patients, as the most of the latter were at stage I 
of PND score when compared to ATTR-FAP population (90% vs 33%, respectively; 
p=0.028). Due to this asymmetric distribution between the two patients’ group according 
to the clinical stages, and the absence of de novo ATTR amyloidosis patients in PND 
stages greater than II, we considered only stage I and II patients for morphometric 
studies.  
The de novo ATTR amyloidosis population exhibited higher large (Z= –3.47; p = 
Table III – Myelinated fiber densities of ATTR-FAP in PND stage ≤ II according to the 
presence or absence of amyloid deposits in sural nerve biopsy 
 
ATTR-FAP patients 
without amyloid deposits 
(n=10) 
ATTR-FAP patients 
with amyloid deposits 
(n=76) 
p value 
Pathology of the sural nervea   
Total myelinated fiber 
density, n/mm2 5244 ± 3660 1407 ± 1592 0.001 
Large myelinated fiber 
density, n/mm2 2739 ± 1802 926 ± 1022 0.001 
Small myelinated fiber 
density, n/mm2 2506 ± 1989 486 ± 696 0.001 
ATTR-FAP – familial amyloid polyneuropathy with thransthyretin mutation 
a Values are expressed as mean ± SD; 
Statistical analyses were performed using the Mann-Whitney U test. 
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0.002), small (Z= –2.98; p = 0.009), and therefore higher total (Z= –3.31; p = 0.003) MF 
densities than did ATTR-FAP patients. Despite their lower total, large and small MF 
densities, no statistically significant differences were observed in these parameters 
between de novo ATTR amyloidosis patients and controls. However, the de novo ATTR 
amyloidosis patients showed lower ratio of small to large MF densities than did controls 
(Z= –2.50; p = 0.037).  
Considering the same time gap from onset of symptoms to nerve biopsy in the same 
clinical stages, de novo ATTR amyloidosis patients continued to show higher total (Z= –
3.15; p = 0.005), large (Z= –3.26; p = 0.003), and small (Z= –2.95; p = 0.009) MF 
densities than of TTR-FAP patients.  
Seven out of ten patients with acquired ATTR exhibited amyloid deposits in sural nerve 
biopsy, as well as 23 out of 24 TTR-FAP patients in the same clinical conditions (p>0.05)  
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DISCUSSION 
In the current study, we established the morphometric pattern of peripheral neuropathy 
in ATTR-FAP and de novo ATTR amyloidosis. The earliest lesions found in the peripheral 
nerve in ATTR-FAP are degeneration of unmyelinated and small myelinated fibers, 
simultaneously with, although in a somewhat erratic manner, amyloid deposition.33 
Several authors have previously reported a size-dependent fiber loss in ATTR-FAP9, 25, 34, 
35, but the precise mechanism of nerve fiber depletion has not yet been fully clarified. 
Ischemia from obliteration or dysfunction of small vessels28, mechanical compression or 
infiltration by the amyloid deposits34, and their metabolic and toxic effects36 are some of 
the adduced pathomechanisms. As expected, our results revealed that ATTR-FAP 
patients have loss of all fiber classes unlike the ones of the asymptomatic mutation 
carriers and controls25, 34, 35, 37, which are in agreement with the clinical manifestation of 
sensorimotor polyneuropathy experimented by the ATTR-FAP patients in the disease 
course. Furthermore, using a larger sample, we also showed that the loss of MF increases 
with disease progression (PND I versus PND II), and that patients in more advanced 
clinical stage showed more frequent amyloid deposition in the nerve. 28, 38 A g-ratio value 
between 0.5 and 0.7 reflects a theoretical optimal value for the conduction velocity of 
nerve impulses.39 Values lower than 0.5 may indicate the presence of degenerated nerve 
fibers with abnormal thickening of the myelin sheath, whereas values higher than 0.7 
denote the presence of demyelinated nerve fibers, or regenerated fibers with thinner 
myelin sheath.39 We found that ATTR-FAP patients had lower mean g-ratio than controls, 
which supports axonal degenerative changes of MF.11, 28, 40 Despite lower numbers of 
ATTR-FAP patients with no amyloid in the sural biopsy, there was a significant higher MF 
density in this group when compared to the amyloid positive group. A previous study did 
not find a clear relationship between the amount of endoneurial amyloid deposition and 
the degree of fiber loss.25 In the present study, we did not performed quantitative 
measures for amyloid deposition and a different clinical scale was used. For analysis 
purposes, this study took in consideration the presence or absence of amyloid, and only 
the earlier clinical stages were considered. Nevertheless, our findings suggest a possible 
direct role of amyloid deposition in disease pathogenesis, at least at this stage of the 
disease. Recently, direct insult of Schwann cells by amyloid fibrils has been suggested, 
particularly in early-onset cases.29 Alternatively, amyloid deposition can represent a 
marker of disease progression, appearing as a consequence of an amyloidogenic 
mechanism but not obligatory as the causative insult. In the previous study, considering 
18 patients in the same disease stage, no correlation between fiber loss and time from 
symptoms onset to biopsy was found.25 In our study, with a larger number of patients, 
despite weak, there was a negative correlation for this analysis. This finding seems to be 
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associated with only large myelinated fibers and only present in the early-onset form of 
the disease. Several studies have reinforced the idea that the differences in clinical 
features between early- and late-onset ATTR-FAP patients correlate well with their 
pathological differences.9, 29 In this larger sample, and in line with other publications11, 29, 
our findings revealed that late-onset patients have more reduced MF densities, particularly 
the large myelinated fibers, than the early-onset ones. These findings corroborate with the 
impairment of all sensory modalities in late-onset cases when compared to the sensory 
dissociation found in early-onset cases.41, 42 As previously described, family history was 
positive in a lower proportion of the late-onset patients, a fact which may lead to a delay in 
diagnosis and poorer patient outcomes at diagnosis and time of nerve biopsy.43-46 In our 
sample, despite similar time gap between disease onset and nerve biopsy, the late-onset 
group was associated with severe PND score at nerve biopsy. Different and additional 
mechanisms must be present to explain this clinical difference. In contrast to various 
descriptions9, 29, we just found slight differences regarding the presence of amyloid 
deposition between both early- and late-onset cases. The amyloid was heavily deposited 
in the two groups, with a discreet predominance in the early-onset patients. An early 
Portuguese report26 unveiled similar findings by opposition to Japanese results29, which 
have revealed that there were abundant amyloid deposits in the sural nerve from early-
onset cases in relation to scarce deposition in the late-onset cases. Additionally, 
differences concerning amyloid composition, congophilic and morphological features have 
been already described between these two groups.7, 47  
An early description of pathological features in asymptomatic carriers has already 
disclosed abnormal findings in more than 50% of this population.26 In the present study, 
we extended the number of studied asymptomatic carriers studied and clearly 
demonstrated the loss of small MF, just as the early depletion of unmyelinated fibers, 
already exists in these subjects several years before symptom onset. The presence of 
greater MF diameters in the symptomatic and asymptomatic ATTR-FAP subjects, together 
with the lower ratio of small to large MF in these groups in comparison to controls, 
reinforces the fact that the small MF are early and preferentially involved in this 
neuropathy. Our findings support the recent reported changes in imaging studies with 
magnetic resonance neurography and peripheral nerve cross sectional areas assessed 
through ultrasonography in asymptomatic ATTR-FAP subjects, and confirms that the 
pathological mechanisms starts in a pre-symptomatic stage.48, 49 Approximately only one 
third of the asymptomatic mutation carriers showed amyloid deposits in their sural nerve 
biopsies. Contrarily to the symptomatic FAP patients group, we did not find differences in 
MF densities between the subjects with and without amyloid deposits in the sural nerve. 
This goes in agreement with previous reported data on asymptomatic gene carriers.50 
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Together with evidence of axonal degeneration already there, this finding suggests the 
importance of other factors in this disorder and/or of toxicity of non-fibrillar ATTR 
aggregates at this stage.50-52 Considering a biological continuum, fibrillar amyloid seems 
to add pathological insult in a second phase of the disease.  
Despite extensive knowledge of epidemiological and genetic factors, it remains 
impossible to predict the age at onset of clinical symptoms in asymptomatic mutation gene 
carriers.12 Furthermore, in this population, some subjective complaints related to anxiety 
due to the knowledge of developing such devastating disease at unknown time in the 
future are difficult to differentiate from true disease onset. For the first time we described a 
longitudinal follow-up study that showed a positive correlation between the MF density 
and the time to disease onset in the asymptomatic mutated gene carriers that developed 
early-onset form of ATTR-FAP. Surprisingly, taking into account that small MF loss are 
initially affected in the disease process, our results suggests that the loss of small MF 
occurs in an independent way of the time for disease progression, and that the turning 
point to become symptomatic seems to be the loss of large MF. Interestingly, the negative 
correlation between time since symptoms onset and myelinated fiber densities in TTR-
FAP patients was only observed in the large myelinated fibers. Moreover, it strengthens 
the fact that late-onset cases are more heterogeneous in terms of clinical presentation 
and pathological features9, but also in terms of prediction for disease onset regarding 
nerve fiber loss. Despite the absence of association between the presence of amyloid and 
MF loss, the presence of amyloid in the biopsy was associated to a short period to 
disease onset. The statistical model also revealed that these associations (MF loss and 
amyloid presence) were stronger for the female subjects.  
De novo ATTR amyloidosis is a well-established complication in DLT recipients from 
TTR-FAP patients. Different authors have described similar pathological53, 54 and clinical 
features between ATTR-FAP and de novo ATTR amyloidosis patients.17, 55 They unveiled 
an asymmetric depletion of nerve fibers, with predominant loss of the small ones 
associated with initial symptoms of length dependent small fiber polyneuropathy, affecting 
pain and thermal sensory modalities and autonomic function.55 In this study, we noticed 
that de novo ATTR amyloidosis patients had an intermediate density of myelinated fibers, 
having densities ranging between the hereditary FAP patients and controls MF density 
vales. Additionally, we found a lower ratio of small to large MF compared to controls, 
confirming a higher reduction of small MF. A simplistic explanation for patients with de 
novo ATTR amyloidosis presenting higher densities of all fiber modalities than did 
hereditary patients, matched for the same clinical stage at nerve biopsy, could be the 
shorter time gap between symptoms onset and biopsy in the former. However, even when 
considering the same time gap from onset of symptoms to nerve biopsy for both groups, 
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de novo ATTR amyloidosis cases maintained higher values of MF densities when 
compared to ATTR-FAP patients. De novo amyloidosis is similar to inherited ATTR-FAP in 
terms of the frequency of found amyloid deposition and the predominant involvement of 
small fibers. The reason for lesser magnitude of fiber loss, together with a shorter period 
to disease onset to what was theoretical conceivable, taking into account the natural 
history of the inherited FAP, remains to be explained. Age, previous incipient neuropathy 
of other origin, and contemporary immunosuppressive drugs are factors that can promote 
amyloidogenesis and accelerate onset of neuropathy in these patients.55 Further studies 
will be necessary to identify such factors and explain their role in the pathophysiology of 
the disease.  
This study has limitations. Despite detailed clinical records from the Corino de Andrade 
Unit, this is a retrospective study. Also, we only assessed the morphometric features of 
this polyneuropathy with respect to the myelinated fibers, wherefore, for a better 
understanding of the disease’s pathogenesis, it would therefore be important to evaluate 
other pathological features such as amyloid composition and ultrastructure findings.  
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CONCLUSIONS 
In this study, we performed detailed morphometric analysis in a large ATTR-FAP 
sample including asymptomatic mutation gene carriers, patients in different disease 
stages and acquired ATTR amyloidosis post liver transplant. We were able to 
demonstrate the initial involvement of small fibers that started in pre-symptomatic stage, 
the correlation of the fiber loss with the disease stage in the earlier stages and the axonal 
nature of the neuropathy. We hypothesized that amyloid deposition can have a direct role 
in disease mechanism in the earlier symptomatic stages. For the first time, we performed 
this analysis with such extended clinical follow up in a group of asymptomatic mutation 
carriers that have undergone sural nerve biopsy. We found that large myelinated fiber loss 
and amyloid deposition are pathological features that correlated independently to a 
shorter period to symptoms onset. These associations were only observed for the early-
onset form of the disease and stronger for the female subjects. Our data supports the idea 
that early-onset form of the disease may follow a biological disease model more linearly 
associated to amyloid deposition and degree of fiber loss, however, with these two 
variables not correlated at this stage. Unmyelinated and small myelinated fiber loss start 
independently of fibrillar amyloid deposition, with the latter probably adding direct insult to 
an ongoing process, accelerating disease onset and progression. At this stage large 
myelinated fibers started to become involved. Finally, we concluded that de novo ATTR 
amyloidosis have similar pathological findings to their inherited counterparts, but with 
lesser degrees of fiber loss for the same disease clinical stage.  
We believe this description will be therapeutically relevant, as it would allow for a better 
interpretation of the role of disease-modifying agents in ATTR amyloidosis.  
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